Highest-materiality recent filing
ArriVent BioPharma announces 2026 annual meeting voting results; directors elected, auditor ratified
Stockholders elected James Healy, John Hohneker, and Stuart Lutzker as Class II directors for three-year terms.
ArriVent BioPharma expands at-the-market equity program by up to $250M
Filed prospectus supplement on May 11, 2026 to sell up to $250,000,000 of common stock via ATM.
ArriVent Q1 net loss $43.3M; cash $326.4M; Phase 3 firmonertinib data mid-2026
Net loss of $43.3M for Q1 2026 versus $64.4M in Q1 2025; R&D expenses $37.6M (down 39% YoY).
ArriVent to present preclinical data on firmonertinib and ARR-002 at AACR 2026
Firmonertinib preclinical data shows high potency and brain penetrance; supports ongoing Phase 3 in EGFR ex20ins NSCLC.
ArriVent reports FY2025 net loss of $166.3M; cash of $312.8M funds into 3Q 2027
Cash and investments of $312.8M as of Dec 31, 2025; expected to fund operations into 3Q 2027.
ArriVent reports Q3 net loss $130.8M; cash $305.4M funds into mid-2027
Net loss $130.8M for nine months ended Sep 30, 2025, up from $59.9M in 2024, driven by R&D spend including $40M upfront for ARR-217.
ArriVent reports 16.0-month mPFS with firmonertinib in EGFR PACC NSCLC Phase 1b final analysis
Median PFS 16.0 months by BICR with firmonertinib 240 mg once daily in first-line EGFR PACC NSCLC.
ArriVent Q2 2025 net loss $95.8M; firmonertinib PACC data positive; ADC ARR-217 dosed
Cash and investments $254.5M at June 30, plus $81.1M raised in July 2025 public offering; runway extended to mid-2027.
ArriVent projects topline phase 3 FURVENT data for firmonertinib in early 2026
Topline firmonertinib monotherapy data from pivotal Phase 3 FURVENT study in 1L NSCLC EGFR exon20ins projected early 2026.
ArriVent BioPharma prices $75M public offering of common stock and pre-funded warrants
Raised ~$75M gross; priced 2,482,692 shares at $19.50 and 1,363,469 pre-funded warrants at $19.4999.
Positive Phase 1b firmonertinib data; 16.0 mo mPFS at 240 mg; global Phase 3 ALPACCA planned H2 2025
16.0 months median PFS by BICR at 240 mg dose in first-line EGFR PACC mutant NSCLC; 68.2% confirmed ORR at 240 mg.
ArriVent shareholders elect Yao and Peterson to board, ratify PwC as auditor
Quorum of 73.89% (25.2M shares) present at June 18 annual meeting.
ArriVent Q1 cash $205.5M, net loss $64.4M; Phase 3 enrollment completed for firmonertinib
Cash $205.5M as of March 31, 2025; net loss $64.4M (vs $17.4M YoY) due to $40M upfront payment to Lepu for ARR-217.
ArriVent appoints Merdad Parsey to board; Carl Gordon not standing for re-election
Carl L. Gordon not standing for re-election at 2025 annual meeting (June 18); no disagreement with company.
ArriVent BioPharma dismisses KPMG, appoints PwC as new auditor
Audit Committee dismissed KPMG on March 11, 2025; no disagreements on accounting principles or audit scope.
ArriVent reports FY2024 net loss $80.5M; cash $266.5M; Phase 3 trial enrollment achieved
Cash and investments of $266.5M as of Dec 31, 2024; expected to fund operations into 2026.
ArriVent licenses ADC MRG007 from Lepu Biopharma; upfront $47M, total potential $1.16B
Exclusive global rights outside Greater China for MRG007, a preclinical ADC targeting GI cancers.
Cash and cash equivalents $282.9M as of Sept 30, 2024; expected to fund operations into 2026.
ArriVent: firmonertinib shows 81.8% ORR in EGFR PACC mutant NSCLC Phase 1b data
81.8% ORR and 63.6% confirmed ORR by BICR at 240mg dose in first-line EGFR PACC mutant NSCLC.
ArriVent Q2 net loss $39.3M; cash $298.7M funds into 2026; firmonertinib data at WCLC
Net loss for six months ended June 30, 2024 was $39.3M, compared to $33.7M in prior year period.
ArriVent appoints Kristine Peterson to Board; she joins Compensation Committee
Kristine Peterson appointed as Class III director effective April 20, 2024, until 2027 annual meeting.
ArriVent BioPharma appoints Dr. Hohneker to two board committees
Dr. John Hohneker appointed to Nominating and Corporate Governance Committee, effective July 3, 2024.
ArriVent BioPharma enters ADC collaboration with Alphamab; milestones up to $615.5M
Collaboration to discover, develop, and commercialize novel antibody drug conjugates (ADCs) for cancers.
ArriVent BioPharma appoints John Hohneker, M.D., to Board of Directors
John Hohneker, M.D., appointed to Board of Directors effective May 16, 2024 as Class II Director.
ArriVent Q1 net loss $17.4M; cash $317.4M; fully enrolled PACC cohort, initiated combo study
Cash and equivalents $317.4M as of March 31, 2024, expected to fund operations into 2026.
ArriVent BioPharma appoints Kristine Peterson to Board of Directors
Appointment effective April 20, 2024; Peterson to serve as Class III Director until 2027 annual meeting.
Arrivent Biopharma reports FY 2023 net loss of $69.3M; cash runway into 2026 after $201M IPO
R&D expenses $64.9M in 2023, up from $30.4M in 2022 on increased furmonertinib trial spending.
ArriVent BioPharma completes IPO of 9.7M shares at $18, raising ~$175M
IPO of 9,722,222 shares of common stock at $18.00 per share closed January 30, 2024.
the Board approved, effective April 28, 2025, an increase in the size of the Board from seven (7) directors to eight (8) directors and appointed Merdad Parsey, M.D., Ph.D. to fill the newly created vacancy on the Board
On April 23, 2025, Carl L. Gordon, Ph.D., CFA notified the board of directors (the “Board”) of ArriVent BioPharma, Inc. (the “Company”) of his decision not to stand for re-election to the Board at the end of his current term at the Company’s 2025 annual meeting of stockholders currently expected to be held on June 18, 2025
On April 20, 2024, the Board of Directors (the “Board”) of ArriVent BioPharma, Inc. (the “Company”) appointed Kristine Peterson to the Board, effective immediately (the “Effective Date”).
On May 16, 2024, the Board of Directors (the “Board”) of ArriVent BioPharma, Inc. (the “Company”) appointed John Hohneker, M.D., to the Board, effective as of May 16, 2024 (the “Effective Date”).
On April 20, 2024, the Board of Directors (the “Board”) of ArriVent BioPharma, Inc. (the “Company”) appointed Kristine Peterson to the Board, effective immediately
Max materiality 0.80 · Median 0.60 · Most common event other_material